Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
198 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Allergic Rhinitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H1 2015', provides an overview of the Allergic Rhinitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Allergic Rhinitis Overview 9 Therapeutics Development 10 Pipeline Products for Allergic Rhinitis - Overview 10 Pipeline Products for Allergic Rhinitis - Comparative Analysis 11 Allergic Rhinitis - Therapeutics under Development by Companies 12 Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 16 Allergic Rhinitis - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Allergic Rhinitis - Products under Development by Companies 20 Allergic Rhinitis - Products under Investigation by Universities/Institutes 26 Allergic Rhinitis - Companies Involved in Therapeutics Development 27 3M Drug Delivery Systems 27 Adamis Pharmaceuticals Corporation 28 ALK-Abello A/S 29 AnaptysBio, Inc. 30 Axikin Pharmaceuticals, Inc. 31 BioTech Tools s.a. 32 ELORAC, Inc. 33 FAES Farma SA 34 Fountain Biopharma Inc. 35 GenMont Biotech Inc. 36 GlaxoSmithKline plc 37 Glenmark Pharmaceuticals Ltd. 38 GlycoMar Limited 39 HAL Allergy BV 40 Hanmi Pharmaceuticals, Co. Ltd. 41 Hisamitsu Pharmaceutical Co., Inc. 42 Johnson & Johnson 43 Laboratorios LETI S.L. 44 Ligand Pharmaceuticals, Inc. 45 Marinomed Biotechnologie GmbH 46 Merck & Co., Inc. 47 Mitsubishi Tanabe Pharma Corporation 48 Nektar Therapeutics 49 NeoPharm Co., Ltd. 50 Novartis AG 51 Nuvo Research Inc. 52 Ono Pharmaceutical Co., Ltd. 53 Oxagen Limited 54 Panmira Pharmaceuticals, LLC. 55 Pfizer Inc. 56 Protectimmun GmbH 57 Revance Therapeutics, Inc. 58 Rottapharm SpA 59 Shionogi & Co., Ltd. 60 Stallergenes S.A. 61 Sun Pharma Advanced Research Company Ltd. 62 Trimel BioPharma SRL 63 VentiRx Pharmaceuticals, Inc. 64 Xencor, Inc. 65 Ziarco Pharma Ltd 66 Allergic Rhinitis - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Combination Products 68 Assessment by Target 69 Assessment by Mechanism of Action 71 Assessment by Route of Administration 73 Assessment by Molecule Type 75 Drug Profiles 77 (azelastine hydrochloride + mometasone furoate) - Drug Profile 77 (fluticasone furoate + levocabastine hydrochloride) - Drug Profile 78 (GSP 301-1 NS + GSP 301-2 NS) - Drug Profile 79 (montelukast sodium + levocetirizine dihydrochloride) - Drug Profile 80 854-A - Drug Profile 81 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 82 Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 83 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 85 allergenic pollen extract of timothy - Drug Profile 86 AM-211 - Drug Profile 87 AM-461 - Drug Profile 89 ANB-020 - Drug Profile 91 andolast - Drug Profile 92 APC-3000 - Drug Profile 93 Arabinogalactan - Drug Profile 94 AVANZ Olive Immunotherapy for Allergic Rhinitis - Drug Profile 95 Avanz Phleum Pratense - Drug Profile 96 bepotastine besylate - Drug Profile 97 bilastine - Drug Profile 99 budesonide - Drug Profile 100 C-525 - Drug Profile 101 CBP-174 - Drug Profile 102 cidoxepin hydrochloride - Drug Profile 103 Depigoid Birch - Drug Profile 104 Dermatophagoides Pteronyssinus Allergen Extract - Drug Profile 105 desloratadine - Drug Profile 106 Drug for Japanese Cedar Pollen Allergy - Drug Profile 107 esketamine - Drug Profile 108 FB-825 - Drug Profile 110 fevipiprant - Drug Profile 111 fluticasone furoate - Drug Profile 113 GLY-079 - Drug Profile 116 GLY-145 - Drug Profile 117 GMNL-32 - Drug Profile 118 gpASIT + TM - Drug Profile 119 GSK-2245035 - Drug Profile 121 HP-3060 - Drug Profile 123 Lactococcus lactis G121 - Drug Profile 124 levocabastine hydrochloride - Drug Profile 125 MAM-06301 - Drug Profile 126 MK-8237 - Drug Profile 127 NKTR-125 - Drug Profile 128 NPB-3 - Drug Profile 129 OC-2417 - Drug Profile 130 OC-459 - Drug Profile 131 Olea Europaea Pollen Extract - Drug Profile 133 ONO-4053 - Drug Profile 134 PF-06444752 - Drug Profile 135 PF-06444753 - Drug Profile 136 rBet v1 - Drug Profile 137 rE58 - Drug Profile 139 RT-001 - Drug Profile 140 S-524101 - Drug Profile 142 S-555739 - Drug Profile 144 Small Molecule for Allergic Rhinitis - Drug Profile 145 Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 146 Small Molecules to Inhibit Histamine H3 Receptor for Nasal Congestion and Allergic Rhinitis - Drug Profile 147 Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 148 Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders - Drug Profile 149 SUN-0597 - Drug Profile 150 SUNL-731 - Drug Profile 152 TBS-6 - Drug Profile 153 Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile 154 VAK-694 - Drug Profile 155 VTX-1463 - Drug Profile 157 VTX-378 - Drug Profile 158 WF-10 - Drug Profile 159 WF-10 liposomal - Drug Profile 161 XmAb-7195 - Drug Profile 162 ZPL-868087 - Drug Profile 163 Allergic Rhinitis - Recent Pipeline Updates 164 Allergic Rhinitis - Dormant Projects 176 Allergic Rhinitis - Discontinued Products 183 Allergic Rhinitis - Product Development Milestones 185 Featured News & Press Releases 185 Appendix 192 Methodology 192 Coverage 192 Secondary Research 192 Primary Research 192 Expert Panel Validation 192 Contact Us 193 Disclaimer 193
List of Tables Number of Products under Development for Allergic Rhinitis, H1 2015 15 Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H1 2015 16 Number of Products under Development by Companies, H1 2015 18 Number of Products under Development by Companies, H1 2015 (Contd..1) 19 Number of Products under Development by Companies, H1 2015 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2015 21 Comparative Analysis by Late Stage Development, H1 2015 22 Comparative Analysis by Clinical Stage Development, H1 2015 23 Comparative Analysis by Early Stage Development, H1 2015 24 Products under Development by Companies, H1 2015 25 Products under Development by Companies, H1 2015 (Contd..1) 26 Products under Development by Companies, H1 2015 (Contd..2) 27 Products under Development by Companies, H1 2015 (Contd..3) 28 Products under Development by Companies, H1 2015 (Contd..4) 29 Products under Development by Companies, H1 2015 (Contd..5) 30 Products under Investigation by Universities/Institutes, H1 2015 31 Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H1 2015 32 Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 33 Allergic Rhinitis - Pipeline by ALK-Abello A/S, H1 2015 34 Allergic Rhinitis - Pipeline by AnaptysBio, Inc., H1 2015 35 Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H1 2015 36 Allergic Rhinitis - Pipeline by BioTech Tools s.a., H1 2015 37 Allergic Rhinitis - Pipeline by ELORAC, Inc., H1 2015 38 Allergic Rhinitis - Pipeline by FAES Farma SA, H1 2015 39 Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H1 2015 40 Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H1 2015 41 Allergic Rhinitis - Pipeline by GlaxoSmithKline plc, H1 2015 42 Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 43 Allergic Rhinitis - Pipeline by GlycoMar Limited, H1 2015 44 Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2015 45 Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 46 Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2015 47 Allergic Rhinitis - Pipeline by Johnson & Johnson, H1 2015 48 Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H1 2015 49 Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 50 Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2015 51 Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2015 52 Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 53 Allergic Rhinitis - Pipeline by Nektar Therapeutics, H1 2015 54 Allergic Rhinitis - Pipeline by NeoPharm Co., Ltd., H1 2015 55 Allergic Rhinitis - Pipeline by Novartis AG, H1 2015 56 Allergic Rhinitis - Pipeline by Nuvo Research Inc., H1 2015 57 Allergic Rhinitis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 58 Allergic Rhinitis - Pipeline by Oxagen Limited, H1 2015 59 Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H1 2015 60 Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2015 61 Allergic Rhinitis - Pipeline by Protectimmun GmbH, H1 2015 62 Allergic Rhinitis - Pipeline by Revance Therapeutics, Inc., H1 2015 63 Allergic Rhinitis - Pipeline by Rottapharm SpA, H1 2015 64 Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2015 65 Allergic Rhinitis - Pipeline by Stallergenes S.A., H1 2015 66 Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 67 Allergic Rhinitis - Pipeline by Trimel BioPharma SRL, H1 2015 68 Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 69 Allergic Rhinitis - Pipeline by Xencor, Inc., H1 2015 70 Allergic Rhinitis - Pipeline by Ziarco Pharma Ltd, H1 2015 71 Assessment by Monotherapy Products, H1 2015 72 Assessment by Combination Products, H1 2015 73 Number of Products by Stage and Target, H1 2015 75 Number of Products by Stage and Mechanism of Action, H1 2015 77 Number of Products by Stage and Route of Administration, H1 2015 79 Number of Products by Stage and Molecule Type, H1 2015 81 Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2015 169 Allergic Rhinitis - Dormant Projects, H1 2015 181 Allergic Rhinitis - Dormant Projects (Contd..1), H1 2015 182 Allergic Rhinitis - Dormant Projects (Contd..2), H1 2015 183 Allergic Rhinitis - Dormant Projects (Contd..3), H1 2015 184 Allergic Rhinitis - Dormant Projects (Contd..4), H1 2015 185 Allergic Rhinitis - Dormant Projects (Contd..5), H1 2015 186 Allergic Rhinitis - Dormant Projects (Contd..6), H1 2015 187 Allergic Rhinitis - Discontinued Products, H1 2015 188 Allergic Rhinitis - Discontinued Products (Contd..1), H1 2015 189
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
